PET MRI in Coronary Artery Disease

Combined Magnetic Resonance Coronary Angiography and Positron Emission Tomography in Patients With Coronary Artery Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03451448

Enrollment

Registered

2018-03-01

Start date

2018-02-01

Completion date

2024-01-31

Last updated

2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

PET/MRI, ultra-small-superparamagnetic particles

Brief summary

This study will assess the use of position emission tomography/magnetic resonance imaging (PET/MRI) using ultra-small-superparamagnetic particles of iron oxide (USPIO) as a contrast agent in patients with coronary artery disease.

Detailed description

Positron emission tomography/magnetic resonance imaging (PET/MRI) has the potential to provide detailed information on coronary artery anatomy, the presence of coronary artery stenosis, the composition of atherosclerotic plaque using MRI tissue characterisation and information about the underlying biological processes using targeted PET tracers. Ultra-small-superparamagnetic particles of iron oxide (USPIO) have a long blood pool half-life so are an ideal contrast agent for PET/MRI imaging. This study will assess the use of PET/MRI with USPIO in patients with stable coronary artery disease and recent acute myocardial infarction.

Interventions

DIAGNOSTIC_TESTPET/MRI

PET/MRI with USPIO contrast

DIAGNOSTIC_TESTMRI

MRI with USPIO contrast

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Healthy volunteers to undergo MRI imaging will be over the age of 18 years and able to provide informed consent. * Patients with coronary artery disease to undergo PET/MRI will have multi-vessel disease (≥2 vessel coronary artery disease with ≥ 50% cross-sectional luminal stenosis). * able to provide informed consent * over the age of 40 years

Exclusion criteria

* inability or unwillingness to undergo magnetic resonance imaging or positron emission tomography * renal failure (Serum creatinine \>200 umol/L or estimated glomerular filtration rate \<30 mL/min * hepatic failure * pregnancy * inability to provide informed consent * contraindications to undergoing MRI scanning * contraindications to contrast agents not included above including evidence of iron overload, known allergy to constituents of the contrast agents, and anaemia not caused by iron deficiency

Design outcomes

Primary

Measure	Time frame	Description
PET/MRI findings	Immediately after PET/MRI scan	The primary endpoint will be the difference in MRI and PET characteristics of atherosclerotic plaques in patients with and without recent acute coronary syndromes.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026